NVCR
NovoCure: Q2 Earnings Snapshot
Article Summary
HOLD- NovoCure Ltd. (NVCR) reported a loss of $15.7 million in its second quarter, while posting revenue of $183.6 million, both beating analyst expectations.
- The oncology drug developer expects full-year revenue in the range of $710 million to $725 million.
- NovoCure continues to invest heavily in its development pipeline, including clinical-stage programs for multiple myelodysplastic syndromes (MDS) and advanced immuno-endocrine therapies.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 8.5% | 25% | 35.0 ptsBelow Screener (8.5%) - Weak growth |
| EPS Growth Next 5Y ? | 23.5% | 25% | 70.0 ptsGood (23.5%) - Solid outlook |
| Target Price Upside ? | 23.2% | 20% | 70.0 ptsGood Upside (23.2%) - Target: $24.57 vs Current: $19.94 |
| Gross Margin % ? | 75.2% | 15% | 100.0 ptsExceptional (75.2%) - Strong pricing power |
| Drawdown from 52-Wk High ? | 5.4% | 15% | 20.0 ptsBarely a Dip (5.4%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVCR
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
- Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
- The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.